# Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3

> **NCT05738980** · NA · RECRUITING · sponsor: **Beijing Hospital** · enrollment: 88 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** Autologous RAK cells

## Key facts

- **NCT ID:** NCT05738980
- **Lead sponsor:** Beijing Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2023-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05738980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05738980, "Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05738980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*